The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the drug Actemra for the treatment of hospitalized Covid-19 adults and pediatric patients.
If you are not happy with the results below please do another search
50 search results for:
Genetic sequences from more than 200 virus samples of early Covid-19 cases mysteriously disappeared from an online scientific database. A researcher in Seattle reported the recovery of 13 of those original sequences.
Med Ad News caught up with Fingerpaint Partner Bill McEllen; Colleen Carter, head of corporate marketing and business development at Fingerpaint; and Splice Co-Founder Paul Hagopian. The West Coast healthcare advertising agency Splice was acquired and will be fully integrated within the full-service health and wellness marketing firm Fingerpaint under the name Fingerpaint Bay Area. They talk about the acquisition and what it means to new employees and current clients.
Fulcrum Therapeutics achieved what the company is calling a clinical first. Data from a Phase IIb study showed that using losmapimod to treat facioscapulohumeral muscular dystrophy (FSHD) slowed the progression of the disease and demonstrated improved function in patients.
AbbVie exercised an exclusive right to acquire TeneoOne, an affiliate of TeneoBio, and the company’s lead asset TNB-383B for relapsed or refractory multiple myeloma (R/R MM).
The World Health Organization (WHO) forecasts that people most vulnerable to Covid-19, such as the elderly, will need to get an annual vaccine booster to be protected against variants, an internal document seen by Reuters shows.
Eli Lilly will apply for U.S. health regulator’s accelerated approval during 2021 for the company’s experimental Alzheimer’s drug, weeks after Biogen Inc.’s controversial drug for the disease was approved.
The Pfizer-BioNTech vaccine is highly effective against the Delta variant of Covid-19, a Pfizer official in Israel said on June 24.
Four biotech companies announced Series A rounds: Vita Therapeutics, NuvoAir, Enveda Biosciences, and ImmuneID.
The U.S. Food and Drug Administration granted breakthrough therapy designation to Japanese company Eisai and partner Biogen’s experimental therapy lecanemab for patients with early Alzheimer’s.